Debate over FDA oversight of peptides reflects a broader shift toward consumer-driven health optimization that could affect the insurance industry. The key question is not simply whether peptides work but how rapidly emerging wellness interventions can influence health outcomes and insurance risk before robust evidence becomes available.
Two women approached a booth at a conference in Las Vegas in July 2025 that promised pathways to an “unlimited lifespan.” Each received a peptide injection. Both left in ambulances.1
The women, aged 38 and 51, were hospitalized in critical condition, hooked to ventilators to help them breathe.
Their story captures one side of the peptide debate. The other is fueled by hope. Peptide proponents say they help in recovery and tissue repair, assist with metabolic health, promote weight management, and extend longevity. They point to established peptide-based therapies such as insulin and more recent examples, such as GLP-1s, as success stories.
Now the debate has reached the U.S. Food and Drug Administration (FDA). The central issue is whether certain peptides should be more broadly available through compounding pharmacies. Critics argue that many of these products lack sufficient evidence regarding long-term safety and effectiveness.
At its core, this issue is nothing new. Rather, it is the next chapter in the ongoing debate about what happens when consumer demand, social media promotion, longevity culture, and alternative access channels move faster than evidence, regulation, and risk assessment.
And that puts insurers solidly at the table as interested participants.
Peptides are short chains of amino acids, the building blocks of proteins. Some peptides have established medical uses, such as insulin for diabetes treatment. Others are marketed for wellness, recovery, performance enhancement, weight management, anti-aging, muscle growth, or longevity.
The current surge in interest is part of a broader consumer movement toward health optimization. Peptides are increasingly promoted through wellness clinics, telehealth providers, influencers, podcasts, and direct-to-consumer platforms.
A recent FDA discussion highlighted the growing debate over access to compounded peptide products. Stakeholders – including patients, wellness providers, and some clinicians – are seeking broader access to certain peptides through compounding pharmacies.2 At the same time, regulators and public health experts have raised concerns about limited clinical evidence, long-term safety, product quality, consistency, and oversight.
The FDA faces the challenge of balancing consumer access and innovation with evidence-based medicine and patient safety. The discussion highlights increasing regulatory pressure as peptide use expands faster than the clinical data needed to evaluate many of the products being marketed.
In late July, a panel of doctors, academics, and pharmacists narrowly voted to recommend broader access to six peptide substances through compounding pharmacies. The six are associated with conditions ranging from ulcerative colitis to wound healing.
The FDA is not bound to follow the recommendation. During the two-day session, FDA scientists cited a lack of reliable data for seven substances under review. The panel voted down only one peptide, which was associated with opioid withdrawal and sleep issues.
Opponents, and some supporters, of advancing peptides toward mainstream medical practice point to incidents such as the one at the July 2025 Revolution Against Aging and Death Festival in Las Vegas. There, the two women received peptide injections at a conference booth from a Los Angeles doctor specializing in “age reversal” therapies.
They immediately fell ill and were hospitalized, although both have recovered.
According to media reports, the doctor who injected them did not have permission to practice medicine or dispense prescriptions in Nevada. He asserted the women’s ailments had nothing to do with peptides.2 In March 2026, the doctor was fined $10,000. According to the citation, the injection administered to the two women included at least one peptide that the FDA warns poses a safety risk.1
Opponents cite the case as evidence of poorly understood risks; some supporters cite it as evidence that approval would improve quality control and distribution.
The central issue for insurers is not whether any individual peptide ultimately proves beneficial. Rather, peptides sit alongside other rapidly expanding product categories with implications for our industry.
As peptide use becomes more common, insurers may increasingly encounter products that blur traditional distinctions between prescription medications, supplements, and wellness interventions. Understanding usage patterns, indications, associated health conditions, and potential safety concerns then become increasingly relevant during underwriting.
A similar challenge has emerged with GLP-1 medications. While originally developed for diabetes and obesity management, consumers increasingly are turning to these drugs for broader health optimization, creating new questions around persistence, treatment intent, and long-term risk assessment.
Peptides represent another step in this more-widespread evolution of consumer-led health interventions.
Many claims surrounding peptides involve recovery, metabolism, muscle development, healthy aging, or longevity. However, the long-term impact of these interventions on mortality and morbidity remains largely unquantified.
The same uncertainty exists with several emerging health technologies, including multi-cancer early detection (MCED) testing. While early detection has intuitive appeal, questions remain regarding long-term effects on population mortality, overdiagnosis, and healthcare outcomes.
As with peptides, enthusiasm and adoption currently outpace the availability of definitive long-term evidence.
Broader peptide adoption could generate additional physician visits, specialist consultations, laboratory testing, and monitoring. Potential adverse effects, treatment complications, and product-quality concerns may also influence healthcare-use patterns.
Wearable health technologies provide a useful parallel. Increased access to health metrics can encourage preventive behaviors and earlier medical intervention but also can lead to additional physician consultations, diagnostic evaluations, and follow-up testing.
Peptide use could similarly influence healthcare-use patterns, regardless of whether long-term health benefits are ultimately confirmed.
FDA scrutiny of compounded peptide products suggests regulatory frameworks may continue to evolve as demand increases. Future regulatory decisions could significantly influence access, prescribing patterns, and adoption rates.
Regulators have faced similar challenges with emerging areas such as GLP-1 therapies, direct-to-consumer testing, and novel diagnostic technologies. In each case, policymakers have had to balance innovation, access, consumer demand, patient safety, and evidence generation.
Peptides appear to be the latest example of how rapidly evolving health innovations can test existing regulatory frameworks.
Taken together, these considerations suggest that peptides are less important for insurers as a standalone product category than as part of a broader trend: Consumer health innovations are increasingly reaching scale before their long-term clinical use and actuarial implications are fully understood.
Historically, the insurance industry has relied on established evidence regarding morbidity, mortality, and healthcare use. Emerging wellness technologies and interventions challenge that model by entering the market and achieving widespread use well before long-term outcomes are fully understood.
Whether peptides ultimately improve health outcomes, increase healthcare use, or have a negligible effect on long-term risk remains uncertain. What is clear is that insurers will likely encounter these products with increasing frequency.
As consumer-driven health optimization continues to expand, insurers need to closely monitor not only the therapies themselves but also the broader behavioral and use trends they represent.
RGA is the recognized industry leader in biometric insights that drive meaningful business results. Explore some of those insights today.
